Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.
Representing Richmond at AHA 2025:
Dr Jörg Täubel, Chief Executive Officer
Miquel Serna Pascual, PHD Representative
We look forward to connecting with attendees to discuss Richmond’s expertise in:
Early-phase cardiovascular and cardiometabolic research
First-in-human and dose-ranging studies
Novel biomarkers and digital endpoints
Regulatory engagement and global trial delivery
Patient-first strategies in complex CV trials
If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
